Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Jersey Mike's Subs Inc. Class A Common Stock (JMKE) vs Oruka Therapeutics Inc. Common Stock (ORKA) Price & Performance

Jersey Mike's Subs Inc. Class A Common StockTrade
Oruka Therapeutics Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Jersey Mike's Subs Inc. Class A Common Stock vs Oruka Therapeutics Inc. Common Stock — how do they compare? Jersey Mike's Subs Inc. Class A Common Stock trades at $16.95 (market cap $5.57B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: Jersey Mike's Subs Inc. Class A Common Stock and Oruka Therapeutics Inc. Common Stock are close in size by market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, Jersey Mike's Subs Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Jersey Mike's Subs Inc. Class A Common Stock for 0 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.

JMKEORKA
Market Cap
$5.57B$5.18B
Volume
1,926,450490,798
Sector
Consumer CyclicalHealth
52-Week High
$24.47$113.08
52-Week Low
$16.09$26.19
Typical Hold Time
0 Days0 Days
Enterprise Value
$7.44B$4.31B

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

JMKE
100% Buy0% Sell
Avg holding period · 0 Days
ORKA
100% Buy0% Sell
Avg holding period · 0 Days

About Jersey Mike's Subs Inc. Class A Common Stock

Jersey Mike's Subs Inc. operates and franchises fast-casual submarine sandwich restaurants, with locations in US and Canada and franchise agreements extending to UK and Ireland.

Read more on JMKE →

About Oruka Therapeutics Inc. Common Stock

Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.

Read more on ORKA →